Dr. Julian Golec FRSC

Dr. Julian Golec FRSC trained as a chemist at the University of Hull before starting work in 1981 for Roussel (later Aventis). Here he led a joint team with Vertex to produce pralacasan, the first ICE inhibitor for arthritis. He spent a brief period (1996-98) as Head of Research at Xenova during which Traiquidar, a multidrug resistance inhibitor for oncology, was moved into the clinic and Xenova secured a multimillion-pound collaboration with Eli Lilly on PAI-1 inhibitors for cardiovascular diseases. Julian retired from Vertex Pharmaceuticals, a pioneer in structure-based drug design, as Senior Vice President responsible for the company’s operation in England. During his 18 years at Vertex, the company progressed from its pure research base to the producer of three highly successful drugs to gain its reputation as one of the world’s leading biotechs. While making contributions to Vertex’s global efforts in cystic fibrosis and pain, the Vertex UK site distinguished itself in oncology by producing three oncology clinical candidates: the first aurora/Abl inhibitor and the first ATR inhibitors, two of which continue in clinical trials. 

Read more
Scientific Advisor